SGLT2i Therapy in Islet Transplantation (SIT)

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

NCT Number	NCT07228195
Lead Sponsor	University of Minnesota
Conditions	Partial Islet Function, TPIAT, Diabetes
Enrollment	40 participants
Start Date	2026-07-21
Primary Completion	2028-12-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-22